CRHR1 Antagonists as Novel Treatment Strategies
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Research has provided considerable evidence for the hypothesis that corticotropin-releasing hormone (CRH), the key central coordinator of stress-hormone homeostasis, also plays a role in the development and course of depression and anxiety disorders. Studies using animal models of anxiety, as well as mouse mutants, in which the gene coding for the CRH type 1 receptor (CRHR1) was genetically deleted supported the notion that enhanced CRH/CRHR1 signaling underlies depression and anxiety disorders. Therefore, a number of small nonpeptide molecules that antagonize CRHR1 have been developed. In animal models, these molecules had anxiolytic and other stress-alleviating effects. An initial clinical study showed that CRHR1 antagonism has beneficial effects on depression and anxiety symptoms at doses unharmful to neuroendocrine stress responsivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical and clinical evidence clearly supports the CRH excess production in the development of MDD [35, 97, 98].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [97]
In the citing paper
“Elaborate preclinical studies showing that the overactivation of CRHR 1 by CRH drives the stress system and anxiety-related behaviours, have triggered the development of a number of non-peptidergic, orally available and brain-penetrating CRHR1 antagonists (Holsboer, 2001;Zorrilla & Koob, 2010).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Holsboer, 2001
Citations
Cites
Nemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485
Physiology and pharmacology of corticotropin-releasing factor.
Owens, M. J., & Nemeroff, C. B. (1991) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06673-6 · Cited by 1,142
Timpl, P., Spanagel, R., Sillaber, I., Kresse, A., Reul, J. M. H. M., Stalla, G. K., Blanquet, V., Steckler, T., Holsboer, F., & Wurst, W. (1998) · Nature Genetics · doi:10.1038/520 · Cited by 919
Self-citationChalmers, D., Lovenberg, T., & De Souza, E. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-10-06340.1995 · Cited by 919
Smith, G. W., Aubry, J.-M., Dellu, F., Contarino, A., Bilezikjian, L. M., Gold, L. H., Chen, R., Marchuk, Y., Hauser, C., Bentley, C. A., et al. (1998) · Neuron · doi:10.1016/s0896-6273(00)80491-2 · Cited by 892
Antidepressants and Hypothalamic-Pituitary-Adrenocortical Regulation
HOLSBOER, F., & BARDEN, N. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-2-187 · Cited by 852
Self-citationZobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
Self-citationRaadsheer, F. C., Hoogendijk, W. J. G., Stam, F. C., Tilders, F. J. H., & Swaab, D. F. (2008) · Neuroendocrinology · doi:10.1159/000126778 · Cited by 667
Holsboer, F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)90056-5 · Cited by 654
Self-citationWong, M.-L., Kling, M. A., Munson, P. J., Listwak, S., Licinio, J., Prolo, P., Karp, B., McCutcheon, I. E., Geracioti, T. D., DeBellis, M. D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.325 · Cited by 575
Research works printed but not linked: 6
- Künzel, 2001, J Psychiatr Res.
- Chaki, 1999, Eur J Pharmacol., 371, 205
- Zobel, 2001, J Psychiatr Res.
- De Bellis, 1993, Am J Psychiatry, 656, 656
- Owens, 1991, Physiology and pharmacology of corticotropinreleasing factor, Pharmacol Rev., 43, 425
- 10.1210/endo.133.1.8391426 · doi:10.1210/endo.133.1.8391426 · Paper page
Cited by
Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression
Reul, J. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00117-5 · Cited by 516
Self-citationSocial stress, therapeutics and drug abuse: Preclinical models of escalated and depressed intake
MICZEK, K., YAP, J., & COVINGTONIII, H. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.07.006 · Cited by 338
“Reducing the acute LHPA response to stress and maintaining integrity over its circadian activity is hypothesized to be a promising method for preventing escalations in drug taking (Holsboer, 2001).”
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Woelk, H., Arnoldt, K., Kieser, M., & Hoerr, R. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.004 · Cited by 149
The HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
“Preclinical and clinical evidence clearly supports the CRH excess production in the development of MDD [35, 97, 98].”
Background
Metadata
- Authors
- Holsboer, F.
- Affiliations
- Max Planck Society (DE)
- Corresponding author
- Holsboer, Florian
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2001-07
- Volume
- 6
- Issue
- 7
- Pages
- 590-594
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W794376169
- Cited by
- 30
- References
- 38
- Citations by year
- 2023: 1 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2015: 1 · 2014: 1
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Spectrums (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- corticotropin-releasing factor, depression, anxiety disorders, anxiolytic effects, animal models of anxiety, mouse mutants
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CRHR1 Antagonists as Novel Treatment Strategies. https://app.cochat.ai/papers/10.1017/s1092852900002133
- The paper
- Holsboer, F. (2001). CRHR1 Antagonists as Novel Treatment Strategies. CNS Spectrums. https://doi.org/10.1017/s1092852900002133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.